WHO ICTRP trial
Long-term safety and efficacy of BIVV001 in Previously Treated Patients with…
JPRN-jRCT2031210133 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031210133 |
|---|---|
| Public title | Long-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia A |
| Scientific title | A Phase 3 open-label, multicenter study of the long-term safety and efficacy of intravenous recombinant coagulation factor VIII Fc-von willebrand factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; BIVV001) in previously treated patients with severe hemophilia A |
| Primary sponsor | Tanaka Tomoyuki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | China;Japan;United States;Japan;Argentina;Japan;Australia;Japan;Belgium;Japan;Bulgaria;Japan;Canada;Japan;France;Japan;Germany;Japan;Greece;Japan;Hungary;Japan;Italy;Japan;Netherlands;Japan;Spain;Japa… |
| Conditions | Hemophilia A |
| Interventions | Drug: efanesoctocog alfa (BIVV001) Pharmaceutical form:Solution for Injection, Route of administration: Intravenous |
| Registration date | Apr 6, 2021 |
| Target size | 262 |
| Secondary IDs | NCT04644575;2020-002215-22 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: